Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Chronic Renal Failure

Free Subscription Articles published in Kidney Int Retrieve available abstracts of 72 articles: HTML format

Single Articles

October 2025
1. HARTZ W, Kinniry P
   Hypertriglyceridemia causing dialysis filter lipid deposition.
   Kidney Int. 2025;108:718.
   PubMed    
   
   
   
2. RAVI KS, Mc Causland FR
   Where next for potassium binders in hemodialysis?
   Kidney Int. 2025;108:534-536.
   PubMed     Abstract available
   
   
   
3. WONG G, Teixeira-Pinto A
   Redefining kidney failure: broadening metrics to realize equity in kidney care.
   Kidney Int. 2025;108:532-533.
   PubMed     Abstract available
   
   
   September 2025
4. SMOYER WE, Gillespie BS, Oni L, Nester C, et al
   STRATEGIES FOR THE DEVELOPMENT OF SODIUM-GLUCOSE COTRANSPORTER-2 INHIBITORS FOR KIDNEY PROTECTION IN PEDIATRIC CHRONIC KIDNEY DISEASE: PROCEEDINGS OF A WORKSHOP MEETING IN JULY 2023.
   Kidney Int. 2025 Sep 24:S0085-2538(25)00747-1. doi: 10.1016/j.kint.2025.
   PubMed     Abstract available
   
   
   
5. CIROVIC A, Cirovic A
   Beyond fibroblast growth factor 23-fibroblast growth factor receptor 4: could aldosterone-driven iron deficiency impact cardiac remodeling in chronic kidney disease?
   Kidney Int. 2025;108:499.
   PubMed    
   
   
   August 2025
6. ITO H, Sato T, Sato F, Taniguchi Y, et al
   The Case | Acute neck swelling in a patient undergoing dialysis.
   Kidney Int. 2025;108:335-336.
   PubMed    
   
   
   
7. PIRBUCCUS M, Dufour I, Akachar Y, Goffin E, et al
   "Strawberry milkshake" effluent in a patient undergoing peritoneal dialysis.
   Kidney Int. 2025;108:331.
   PubMed    
   
   
   
8. PICCOLI GB, Orozco A, Shemies R, Attini R, et al
   Postpartum counseling and interventions to reduce the risk of chronic kidney disease: back to the future.
   Kidney Int. 2025;108:160-166.
   PubMed    
   
   
   July 2025
9. FISHBANE S, Dember LM, Jadoul M, Kovesdy CP, et al
   The randomized DIALIZE-Outcomes trial evaluated sodium zirconium cyclosilicate in hemodialysis.
   Kidney Int. 2025 Jul 4:S0085-2538(25)00509-5. doi: 10.1016/j.kint.2025.
   PubMed     Abstract available
   
   
   
10. TEMPLE K, Lester R, Sinclair N, Owen K, et al
    Indigenous spirituality and cultural knowledges provide strength and resilience to Aboriginal people with chronic kidney disease.
    Kidney Int. 2025;108:2-4.
    PubMed    
    
    
    
11. AGARWAL R
    Steroidal or nonsteroidal mineralocorticoid receptor antagonists for reducing cardiovascular burden in chronic kidney disease.
    Kidney Int. 2025;108:11-14.
    PubMed    
    
    
    June 2025
12. RAILLON LA, Florens N, Payelle F, Martin M, et al
    Medium chain fatty acids are potent binding competitors to improve protein-bound uremic toxin clearance during hemodialysis.
    Kidney Int. 2025 Jun 25:S0085-2538(25)00492-2. doi: 10.1016/j.kint.2025.
    PubMed     Abstract available
    
    
    
13. ORTIZ A, Arreola Guerra JM, Chan JCN, Jha V, et al
    Preventing chronic kidney disease and maintaining kidney health: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.
    Kidney Int. 2025 Jun 18:S0085-2538(25)00334-5. doi: 10.1016/j.kint.2025.
    PubMed     Abstract available
    
    
    
14. RIZZOLO K, Villegas L, Cervantes L
    The national landscape of kidney transplantation for undocumented immigrants: advancing kidney transplantation equity.
    Kidney Int. 2025;107:976-979.
    PubMed     Abstract available
    
    
    
15. CHARYTAN DM, Winkelmayer WC, Granger CB, Middleton JP, et al
    Corrigendum to "Effects of dialysate potassium concentration of 3.0 mmol/l with sodium zirconium cyclosilicate on dialysis-free days versus dialysate potassium concentration of 2.0 mmol/l alone on rates of cardiac arrhythmias in hemodialysis patients
    Kidney Int. 2025;107:1123.
    PubMed    
    
    
    May 2025
16. MITROFANOVA A, Fontanella AM, Molina J, Zhang G, et al
    The enzyme SMPDL3b in podocytes decouples proteinuria from chronic kidney disease progression in experimental Alport Syndrome.
    Kidney Int. 2025 May 30:S0085-2538(25)00407-7. doi: 10.1016/j.kint.2025.
    PubMed     Abstract available
    
    
    
17. MUREA M, Torreggiani M, Deira J, Sirich TL, et al
    From Niche to Norm: A Multi-Action Plan to Close Gaps and Mainstream Incremental Hemodialysis.
    Kidney Int. 2025 May 20:S0085-2538(25)00404-1. doi: 10.1016/j.kint.2025.
    PubMed     Abstract available
    
    
    
18. DE BOER IH, Caramori ML, Chan JCN, Heerspink HJL, et al
    GLP-1 receptor agonists and other incretin mimetics for diabetes and chronic kidney disease-a KDIGO commentary.
    Kidney Int. 2025;107:767-771.
    PubMed    
    
    
    April 2025
19. LI F, Lan Q, Wang Y, Xiong J, et al
    Single-cell analysis of proximal tubular cells with different DNA content reveals functional heterogeneity in the acute kidney injury to chronic kidney disease transition.
    Kidney Int. 2025 Apr 21:S0085-2538(25)00332-1. doi: 10.1016/j.kint.2025.
    PubMed     Abstract available
    
    
    
20. ERICKSON KF, Fotheringham J
    Is online hemodiafiltration a cost-effective alternative to conventional hemodialysis?
    Kidney Int. 2025;107:602-605.
    PubMed     Abstract available
    
    
    March 2025
21. STACK AG
    Can we crystallize the role of urate-lowering treatment in chronic kidney disease?
    Kidney Int. 2025;107:394-396.
    PubMed     Abstract available
    
    
    
22. JENSEN M, Jensen BL
    Soluble guanylate cyclase as a direct target for pharmacologic mitigation of chronic kidney disease.
    Kidney Int. 2025;107:391-394.
    PubMed     Abstract available
    
    
    February 2025
23. BONNIN-MARQUEZ A, Jankowski J, Maas SL, Hermann J, et al
    Guanidinylation compromises the anti-inflammatory and anti-oxidative properties of apolipoprotein A-I in chronic kidney disease progression.
    Kidney Int. 2025 Feb 24:S0085-2538(25)00171-1. doi: 10.1016/j.kint.2025.
    PubMed     Abstract available
    
    
    
24. ZHU D, Judge PK, Wanner C, Haynes R, et al
    THE PREVENTION AND MANAGEMENT OF CHRONIC KIDNEY DISEASE AMONG PATIENTS WITH METABOLIC SYNDROME.
    Kidney Int. 2025 Feb 20:S0085-2538(25)00141-3. doi: 10.1016/j.kint.2024.
    PubMed     Abstract available
    
    
    
25. MENON G, Metoyer GT, Li Y, Chen Y, et al
    A national registry study evaluated the landscape of kidney transplantation among presumed unauthorized immigrants in the United States.
    Kidney Int. 2025 Feb 14:S0085-2538(25)00088-2. doi: 10.1016/j.kint.2025.
    PubMed     Abstract available
    
    
    
26. FUCHS MAA, Burke EJ, Latic N, Murray S, et al
    Fibroblast growth factor 23 and fibroblast growth factor receptor 4 promote cardiac metabolic remodeling in chronic kidney disease.
    Kidney Int. 2025 Feb 7:S0085-2538(25)00087-0. doi: 10.1016/j.kint.2025.
    PubMed     Abstract available
    
    
    
27. HSU SN, Stephen LA, Phadwal K, Dillon S, et al
    Mitochondrial dysfunction and mitophagy blockade contribute to renal osteodystrophy in chronic kidney disease-mineral bone disorder.
    Kidney Int. 2025 Feb 6:S0085-2538(25)00085-7. doi: 10.1016/j.kint.2025.
    PubMed     Abstract available
    
    
    
28. HUGHES A, Scholes-Robertson N, Coghlan D, Wu R, et al
    Identifying strategies for disseminating research to patients with chronic kidney disease and caregivers: a workshop report.
    Kidney Int. 2025 Feb 6:S0085-2538(25)00083-3. doi: 10.1016/j.kint.2025.
    PubMed     Abstract available
    
    
    January 2025
29. SCHOUTEN AEM, Fischer F, Blankestijn PJ, Vernooij RWM, et al
    A health economic evaluation of the multinational, randomized controlled CONVINCE trial - cost-utility of high-dose online hemodiafiltration compared to high-flux hemodialysis.
    Kidney Int. 2025 Jan 21:S0085-2538(25)00068-7. doi: 10.1016/j.kint.2024.
    PubMed     Abstract available
    
    
    
30. KETTELER M, Evenepoel P, Holden RM, Isakova T, et al
    Chronic kidney disease-mineral and bone disorder: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.
    Kidney Int. 2025 Jan 10:S0085-2538(24)00810-X. doi: 10.1016/j.kint.2024.
    PubMed     Abstract available
    
    
    
31. HOLE B, Coast J, Caskey FJ, Selman LE, et al
    A choice experiment of older patients' preferences for kidney failure treatments.
    Kidney Int. 2025;107:130-142.
    PubMed     Abstract available
    
    
    
32. WATANABE S, Sawa N, Hiramatsu R, Oba Y, et al
    The Case | A patient with chronic kidney disease and new-onset heart failure.
    Kidney Int. 2025;107:195-196.
    PubMed    
    
    
    December 2024
33. MIMURA I, Chen Z, Natarajan R
    Epigenetic alterations and memory: key players in the development/progression of chronic kidney disease promoted by acute kidney injury and diabetes.
    Kidney Int. 2024 Dec 24:S0085-2538(24)00918-9. doi: 10.1016/j.kint.2024.
    PubMed     Abstract available
    
    
    
34. HANOUNEH M, Stewart S, Aktay R, Fang AS, et al
    Chylothorax and chylopericardium in a dialysis patient.
    Kidney Int. 2024;106:1190.
    PubMed    
    
    
    
35. BOBOT M, Burtey S
    New insights into mechanisms underlying cognitive impairment in chronic kidney disease.
    Kidney Int. 2024;106:1020-1022.
    PubMed     Abstract available
    
    
    November 2024
36. AMINI M, Frisch J, Jost P, Sarakpi T, et al
    Purinergic receptor P2X7 regulates interleukin-1alpha mediated inflammation in chronic kidney disease in a reactive oxygen species-dependent manner.
    Kidney Int. 2024 Nov 19:S0085-2538(24)00798-1. doi: 10.1016/j.kint.2024.
    PubMed     Abstract available
    
    
    
37. VAN DEN BERG CW, Dumas SJ, Little MH, Rabelink TJ, et al
    Challenges in maturation and integration of kidney organoids for stem cell-based renal replacement therapy.
    Kidney Int. 2024 Nov 19:S0085-2538(24)00806-8. doi: 10.1016/j.kint.2024.
    PubMed     Abstract available
    
    
    
38. KO TY, Wu CC, Hsieh MY, Yang CW, et al
    A randomized controlled trial evaluated the efficacy and safety of apixaban for prevention of recurrent thrombosis after thrombectomy of hemodialysis vascular access.
    Kidney Int. 2024 Nov 15:S0085-2538(24)00792-0. doi: 10.1016/j.kint.2024.
    PubMed     Abstract available
    
    
    
39. GHANG B, Park J, Lee JS, Lim JS, et al
    Post-hoc analysis of the CARES trial suggests delayed progression of chronic kidney disease in patients with gout during urate-lowering therapy.
    Kidney Int. 2024 Nov 15:S0085-2538(24)00789-0. doi: 10.1016/j.kint.2024.
    PubMed     Abstract available
    
    
    
40. GEORGERY H, Lengele JP, Leflot S, Gillion V, et al
    Recurrent iodine-induced sialadenitis in a patient undergoing hemodialysis: is this really ineluctable?
    Kidney Int. 2024;106:997.
    PubMed    
    
    
    
41. HAMDAN H, Roshanravan B
    Dialysis modality and quality of life: more answers yet more questions.
    Kidney Int. 2024;106:792-794.
    PubMed     Abstract available
    
    
    
42. SHAREEF Z, Spradling M, Blair P, Quinones-Vargas I, et al
    Appendicitis associated with sevelamer use in a patient receiving peritoneal dialysis.
    Kidney Int. 2024;106:1000.
    PubMed    
    
    
    
43. YANAGI T, Kikuchi H, Takeuchi K, Susa K, et al
    ULK1-regulated AMP sensing by AMPK and its application for the treatment of chronic kidney disease.
    Kidney Int. 2024;106:887-906.
    PubMed     Abstract available
    
    
    October 2024
44. IKIZLER TA, Drueke TB, Floege J, Wong G, et al
    Avoiding Arrythmias by Personalizing Dialysate Concentration: A Case for Precision Medicine in Dialysis Patients.
    Kidney Int. 2024 Oct 22:S0085-2538(24)00721-X. doi: 10.1016/j.kint.2024.
    PubMed     Abstract available
    
    
    
45. CHARYTAN DM, Winkelmayer WC, Granger CB, Middleton JP, et al
    Effects of dialysate potassium concentration of 3.0mEq/l with sodium zirconium cyclosilicate on dialysis-free days versus dialysate potassium concentration of 2.0mEq/l alone on rates of cardiac arrhythmias in hemodialysis patients with hyperkalemia.
    Kidney Int. 2024 Oct 22:S0085-2538(24)00722-1. doi: 10.1016/j.kint.2024.
    PubMed     Abstract available
    
    
    
46. BAJAJ A, Arora M, Bhatt U
    The Case | Dark dialysate after colonoscopy.
    Kidney Int. 2024;106:761-762.
    PubMed    
    
    
    
47. SHARMA Y, Tiwari V, Tyagi V, Bhargava V, et al
    CAPD catheter obstruction by fallopian tubes.
    Kidney Int. 2024;106:760.
    PubMed    
    
    
    
48. CHEN WLJ, Fung KFK, Chan EY
    Nephronophthisis-associated ciliopathy with brachydactyly, medullary cysts, and chronic kidney disease.
    Kidney Int. 2024;106:759.
    PubMed    
    
    
    September 2024
49. BISHOP NC
    Unpicking the multi-omic response to endurance training: relevance for exercise benefits in chronic kidney disease.
    Kidney Int. 2024 Sep 18:S0085-2538(24)00646-X. doi: 10.1016/j.kint.2024.
    PubMed    
    
    
    
50. TONG KC, Wee KW
    Cardiovascular disease as a risk factor for frailty in dialysis patients.
    Kidney Int. 2024;106:537-538.
    PubMed    
    
    
    
51. GARG AX, Young A
    Improving the management of chronic kidney disease in primary care by enhancing laboratory reports with additional information and follow-up procedures.
    Kidney Int. 2024;106:366-368.
    PubMed     Abstract available
    
    
    August 2024
52. BERGERON NAD, Candellier A, Rousseau-Gagnon M, Mac-Way F, et al
    Unusual cause of retroperitoneal leak in a patient undergoing peritoneal dialysis.
    Kidney Int. 2024;106:321.
    PubMed    
    
    
    
53. TOUSSAINT ND, Badve SV
    Normalizing serum phosphate based on association, not causation? Lessons in dialysis should have taught us not to fix what we can't prove is broken.
    Kidney Int. 2024;106:195-199.
    PubMed    
    
    
    
54. HAMANO T, Fukagawa M
    Results of the EPISODE trial plead for reasonable practice-based serum phosphate lowering in patients on dialysis.
    Kidney Int. 2024;106:191-195.
    PubMed    
    
    
    July 2024
55. ROSE M, Fischer FH, Liegl G, Strippoli GF, et al
    The CONVINCE randomized trial found positive effects on quality of life for patients with chronic kidney disease treated with hemodiafiltration.
    Kidney Int. 2024 Jul 30:S0085-2538(24)00534-9. doi: 10.1016/j.kint.2024.
    PubMed     Abstract available
    
    
    
56. ZIMMERMANN S, Mathew A, Bondareva O, Elwakiel A, et al
    Chronic kidney disease leads to microglial potassium efflux and inflammasome activation in the brain.
    Kidney Int. 2024 Jul 30:S0085-2538(24)00535-0. doi: 10.1016/j.kint.2024.
    PubMed     Abstract available
    
    
    
57. JOHNSON RJ, Mandell BF, Schlessinger N, Mount DB, et al
    Controversies and practical management of patients with gout and chronic kidney disease.
    Kidney Int. 2024 Jul 19:S0085-2538(24)00473-3. doi: 10.1016/j.kint.2024.
    PubMed     Abstract available
    
    
    
58. STAMELLOU E, Noels H, Floege J
    Factor XI inhibition in hemodialysis patients: the safer anticoagulation?
    Kidney Int. 2024;106:21-23.
    PubMed     Abstract available
    
    
    
59. SAHINOZ M, Ikizler TA
    Inflammasome activation: unraveling the link between chronic kidney disease and atrial fibrillation.
    Kidney Int. 2024;106:6-9.
    PubMed    
    
    
    
60. MEDINA RANGEL PX, Ishibe S
    Preventing MMP23-mediated cleavage of podocyte RARRES1: a novel strategy to halt chronic kidney disease progression?
    Kidney Int. 2024;106:16-18.
    PubMed     Abstract available
    
    
    
61. WONG G, Guha C, Mallitt KA, van Zwieten A, et al
    The randomized controlled trial (NAVKIDS2) of a patient navigator program created for children with chronic kidney disease.
    Kidney Int. 2024 Jul 1:S0085-2538(24)00450-2. doi: 10.1016/j.kint.2024.
    PubMed     Abstract available
    
    
    May 2024
62. CORKEN AL, Ong V, Kore R, Ghanta SN, et al
    Platelets, Inflammation, and Purinergic Receptors in Chronic Kidney Disease.
    Kidney Int. 2024 May 29:S0085-2538(24)00381-8. doi: 10.1016/j.kint.2024.
    PubMed     Abstract available
    
    
    
63. CHAN GC, Kalantar-Zadeh K, Ng JK, Tian N, et al
    Frailty in Patients on Dialysis.
    Kidney Int. 2024 May 3:S0085-2538(24)00315-6. doi: 10.1016/j.kint.2024.
    PubMed     Abstract available
    
    
    
64. GOLDSTEIN CE, Taljaard M, Nicholls SG, Beaucage M, et al
    The Ottawa Statement implementation guidance document for cluster randomized trials in the hemodialysis setting.
    Kidney Int. 2024;105:898-911.
    PubMed     Abstract available
    
    
    
65. CULLIS B, McCulloch M, Finkelstein FO
    Development of PD in lower-income countries: a rational solution for the management of AKI and ESKD.
    Kidney Int. 2024;105:953-959.
    PubMed     Abstract available
    
    
    April 2024
66. WONG G, Bernier-Jean A, Rovin B, Ronco P, et al
    Time for Action: Recognising chronic kidney disease as a major non-communicable disease driver of premature mortality.
    Kidney Int. 2024 Apr 2:S0085-2538(24)00247-3. doi: 10.1016/j.kint.2024.
    PubMed    
    
    
    
67. 
    KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease.
    Kidney Int. 2024;105.
    PubMed    
    
    
    
68. LEVIN A, Ahmed SB, Carrero JJ, Foster B, et al
    Executive summary of the KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease: known knowns and known unknowns.
    Kidney Int. 2024;105:684-701.
    PubMed     Abstract available
    
    
    March 2024
69. WINKELMAYER WC, Lensing AWA, Thadhani RI, Mahaffey KW, et al
    A Phase II randomized controlled trial evaluated antithrombotic treatment with fesomersen in patients with kidney failure on hemodialysis.
    Kidney Int. 2024 Mar 25:S0085-2538(24)00196-0. doi: 10.1016/j.kint.2024.
    PubMed     Abstract available
    
    
    
70. PIETERS TT, Besseling PJ, Bovee DM, Rookmaaker MB, et al
    Discrepancies between transcutaneous and estimated glomerular filtration rates in rats with chronic kidney disease.
    Kidney Int. 2024 Mar 19:S0085-2538(24)00187-X. doi: 10.1016/j.kint.2024.
    PubMed     Abstract available
    
    
    
71. GILL JS, Chadban SJ
    Pretransplant screening for coronary artery disease: data are required before practice change.
    Kidney Int. 2024;105:470-472.
    PubMed     Abstract available
    
    
    February 2024
72. LEE J, Lee J, Kim K, Lee J, et al
    Antibiotic-induced intestinal microbiota depletion can attenuate the acute kidney injury to chronic kidney disease transition via NADPH oxidase 2 and trimethylamine-N-oxide inhibition.
    Kidney Int. 2024 Feb 29:S0085-2538(24)00163-7. doi: 10.1016/j.kint.2024.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Chronic Renal Failure is free of charge.